Susan O’Brien

52.9k citations

840 papers · 36.5k indexed · 8 hit papers · h-index 100

Impact in

Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research

Papers in

Genetics 557
- Chronic Lymphocytic Leukemia Research 502
- Myeloproliferative Neoplasms: Diagnosis and Treatment 42
Hematology 532
- Chronic Myeloid Leukemia Treatments 355
- Acute Myeloid Leukemia Research 232

Co-authors: Hagop M. Kantarjian Jörge E. Cortes Michael J. Keating Francis J. Giles Stefan Faderl Deborah A. Thomas Guillermo Garcia‐Manero Farhad Ravandi
Journals: Blood (360 papers)Cancer (130 papers)Journal of Clinical Oncology (89 papers)American Journal of Hematology (18 papers)British Journal of Haematology (17 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Susan O’Brien

820 papers receiving 35.6k citations

Hit Papers

8 papers align trajectories log scale

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia 2015 · 350 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Blood
2011 Blood
2008 Blood
2006 Blood
2005 Journal of Clinical Oncology
2000 Blood
1999 New England Journal of Medicine
1997 Blood

Peers

Countries citing papers authored by Susan O’Brien

Since Specialization

Citations

This map shows the geographic impact of Susan O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan O’Brien more than expected).

Fields of papers citing papers by Susan O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan O’Brien. The network helps show where Susan O’Brien may publish in the future.

Co-authors

The 25 scholars most cited alongside Susan O’Brien, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Susan O’Brien Line = papers co-authored together Susan O’Brien links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results American Journal of Hematology ·Hagop M. Kantarjian, Nicholas J. Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fadi Haddad, Issa F. Khouri, Courtney D. DiNardo, Naveen Pemmaraju, William G. Wierda, Guillermo Garcia‐Manero, Partow Kebriaei, Rebecca Garris, Sanam Loghavi, Jeffrey L. Jorgensen, Monica Kwari, Susan O’Brien, Farhad Ravandi, Elias Jabbour	2023	45
2	A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations) Blood ·Anjali S. Advani, Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron T. Gerds, Susan O’Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba	2021	9
3	Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience Blood Advances ·Guillaume Richard‐Carpentier, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Fadi Haddad, Nitin Jain, Farhad Ravandi, Nicholas J. Short, Courtney D. DiNardo, Koichi Takahashi, Marina Konopleva, Naval Daver, Tapan M. Kadia, Guillermo Garcia‐Manero, Rebecca Garris, Susan O’Brien, Elias Jabbour	2021	25
4	Long‐term results of frontline dasatinib in chronic myeloid leukemia Cancer ·Abhishek Maiti, Jörge E. Cortes, Keyur P. Patel, Lucia Masárová, Gautam Borthakur, Farhad Ravandi, Srđan Verstovšek, Alessandra Ferrajoli, Zeev Estrov, Guillermo Garcia‐Manero, Tapan M. Kadia, Graciela M. Nogueras‐González, Jeffrey Skinner, Yanti Desnita-Tasri, Sara Dellasala, Rajyalakshmi Luthra, Elias Jabbour, Susan O’Brien, Hagop M. Kantarjian	2020	24
5	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs Blood Advances ·Preetesh Jain, Hagop M. Kantarjian, Prajwal Boddu, Graciela M. Nogueras‐González, Srđan Verstovšek, Guillermo Garcia‐Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Francis Pantino, Fikriansyah Tjarsadiwiryo, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jörge E. Cortes	2019	85
6	Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia Clinical Lymphoma Myeloma & Leukemia ·Elias Jabbour, Maral DerSarkissian, Mei Sheng Duh, Alberto Garriido, Wendy Y. Cheng, Lisa J. McGarry, Khabat Zandi, Hui Huang, Susan O’Brien, Farhad Ravandi, Hagop M. Kantarjian	2018	44
7	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000 Cancer ·Hagop M. Kantarjian, Courtney D. DiNardo, Graciela M. Nogueras‐González, Tapan M. Kadia, Elias Jabbour, Carlos E. Bueso‐Ramos, Susan O’Brien, Marina Konopleva, Nitin Jain, Naval Daver, Elizabeth J. Shpall, Richard E. Champlin, M. C. M. Young, Guillermo Garcia‐Manero, Michael J. Keating, Xuelin Huang, Jörge E. Cortes, Sherry Pierce, Farhad Ravandi, Emil J. Freireich	2018	20
8	Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex Molecular Cancer Research ·Uri Rozovski, David Harris, Ping Li, Zhiming Liu, Preetesh Jain, Mirjam Jaquemoth, Alessandra Ferrajoli, Jan A. Burger, Susan O’Brien, Prithviraj Bose, Philip A. Thompson, Nitin Jain, William G. Wierda, Michael J. Keating, Zeev Estrov	2017	23
9	The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab British Journal of Haematology ·Preetesh Jain, Graciela M. Nogueras‐González, Rashmi Kanagal‐Shamanna, Uri Rozovski, Nonoka Nakashima, Constantine S. Tam, William G. Wierda, Philip A. Thompson, Nitin Jain, Rajyalakshmi Luthra, Andres Quesada, 一男千々岩, Alessandra Ferrajoli, Jan A. Burger, Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Michael J. Keating, Zeev Estrov	2017	23
10	Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase Cancer ·Koji Sasaki, Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia‐Manero, William G. Wierda, Naval Daver, Alessandra Ferrajoli, Koichi Takahashi, Preetesh Jain, Mary Beth Rios, Sherry Pierce, Elias Jabbour, Jörge E. Cortes	2017	23
11	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia Clinical Cancer Research ·Preetesh Jain, Michael J. Keating, William G. Wierda, Mariela Sivina, Philip A. Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop M. Kantarjian, Susan O’Brien, Jan A. Burger	2016	45
12	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia Clinical Lymphoma Myeloma & Leukemia ·Koji Sasaki, Elias Jabbour, Jörge E. Cortes, Tapan M. Kadia, Guillermo Garcia‐Manero, Gautam Borthakur, Preetesh Jain, Sherry Pierce, Naval Daver, Koichi Takahashi, Susan O’Brien, Hagop M. Kantarjian, Farhad Ravandi	2016	11
13	Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells Molecular Cancer Research ·Uri Rozovski, Srđana Grgurević, Carlos Bueso-Ramos, David Harris, Ping Li, Zhiming Liu, Ji Yuan Wu, Preetesh Jain, William G. Wierda, Jan A. Burger, Susan O’Brien, Nitin Jain, Alessandra Ferrajoli, Michael J. Keating, Zeev Estrov	2015	69
14	The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Blood ·Julia Hoellenriegel, Sarah Meadows, Mariela Sivina, William G. Wierda, Hagop M. Kantarjian, Michael J. Keating, Neill A. Giese, Susan O’Brien, Albert S. Yu, Langdon L. Miller, Brian J. Lannutti, Jan A. Burger Hit paper breakdown →	2011	442
15	Epstein‐Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia Cancer ·Jeffrey J. Tarrand, Michael J. Keating, Apostolia M. Tsimberidou, Susan O’Brien, 신두항, Anna Liv Jonsson, Carlos E. Bueso‐Ramos	2010	21
16	Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome Clinical Cancer Research ·Wanlong Ma, Hagop M. Kantarjian, B. Nebiyou Bekele, Amber C. Donahue, Xi Zhang, Kostiantyn Khadartsev, Susan O’Brien, Elihu H. Estey, Zeev Estrov, Jörge E. Cortes, Michael J. Keating, Francis J. Giles, Maher Albitar	2009	40
17	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood ·Jörge E. Cortes, Elias Jabbour, Hagop Kantarjian, C. Cameron Yin, Jianqin Shan, Susan O’Brien, Guillermo Garcia‐Manero, Francis J. Giles, Esben T. Fjederholt, F Ghinet, William G. Wierda, Dan Jones	2007	230
18	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome Cancer ·Hagop M. Kantarjian, Susan O’Brien, Xuelin Huang, Guillermo Garcia‐Manero, Farhad Ravandi, Jörge E. Cortes, Jianqin Shan, Jan Davisson, Carlos E. Bueso‐Ramos, Jean‐Pierre J. Issa	2007	132
19	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome–positive chronic myelogenous leukemia treated with interferon‐α regimens for early chronic phase Cancer ·Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes, Jianqin Shan, Francis J. Giles, Guillermo Garcia‐Manero, Srđan Verstovšek, Stefan Faderl, Mary Beth Rios, Moshe Talpaz	2003	13
20	Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. PubMed ·Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Razelle Kurzrock, Jordan U. Gutterman, Michael J. Keating, Kenneth B. McCredie, Emil J. Freireich	1997	10

About Susan O’Brien

Susan O’Brien is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Rheumatology and Public Health, Environmental and Occupational Health, having authored 840 papers that have together received 36.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (502 papers), Chronic Myeloid Leukemia Treatments (355 papers), Acute Lymphoblastic Leukemia research (263 papers), Acute Myeloid Leukemia Research (232 papers), Lymphoma Diagnosis and Treatment (207 papers), Eosinophilic Disorders and Syndromes (153 papers), Immunodeficiency and Autoimmune Disorders (57 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (42 papers). The work is most often cited by research in Hematology (21.3k citations), Genetics (17.3k citations), Pathology and Forensic Medicine (8.4k citations), Rheumatology (5.6k citations) and Public Health, Environmental and Occupational Health (8.4k citations). Susan O’Brien has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Michael J. Keating, Francis J. Giles, Stefan Faderl, Deborah A. Thomas, Guillermo Garcia‐Manero, Farhad Ravandi, William G. Wierda and Elias Jabbour. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, American Journal of Hematology and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact